GSK plc vs Lamb Weston Holdings Inc — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while Lamb Weston Holdings Inc trades at $52.79 (market cap $7.23B). The key difference: GSK plc is far larger — about 14.2× Lamb Weston Holdings Inc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | LW | |
|---|---|---|
Market Cap | $102.60B | $7.23B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $66.57 |
52-Week Low | $38.22 | $38.48 |
Enterprise Value | $123.04B | $11.10B |
Dividend Yield | 3.57% | 2.89% |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Lamb Weston (LW) trades at $53.10, up 2.49% with a bullish technical signal. The stock shows strong earnings momentum with four consecutive quarterly beats, including Q2 2026 EPS of $0.87 versus $0.62 expected. Valuation metrics include a P/E of 25.28 and P/S of 1.11. Recent news highlights institutional buying and upcoming management participation in investor events, while fundamentals show $6.45B revenue with 4.39% net margin.
LW presents a mixed outlook with solid operational performance offset by margin pressure. The consensus price target of $53.86 offers limited upside, while analyst sentiment leans neutral (63% Hold). Key risks include international headwinds and cost inflation, but North American volume growth and dividend yield of 3.1% provide support. The stock trades near fair value with balanced risk-reward.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →